"Fluorodeoxyglucose F18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
Concept/Terms
Fluorodeoxyglucose F18- Fluorodeoxyglucose F18
- F18, Fluorodeoxyglucose
- 18F-FDG
- Fluorodeoxyglucose F 18
- F 18, Fluorodeoxyglucose
- Fludeoxyglucose F 18
- F 18, Fludeoxyglucose
- Fluorine-18-fluorodeoxyglucose
- Fluorine 18 fluorodeoxyglucose
- 18F Fluorodeoxyglucose
- Fluorodeoxyglucose, 18F
- 18FDG
Below are MeSH descriptors whose meaning is more general than "Fluorodeoxyglucose F18".
Below are MeSH descriptors whose meaning is more specific than "Fluorodeoxyglucose F18".
This graph shows the total number of publications written about "Fluorodeoxyglucose F18" by people in Harvard Catalyst Profiles by year, and whether "Fluorodeoxyglucose F18" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 5 | 5 |
1995 | 0 | 9 | 9 |
1996 | 0 | 5 | 5 |
1997 | 1 | 11 | 12 |
1998 | 7 | 2 | 9 |
1999 | 5 | 5 | 10 |
2000 | 4 | 6 | 10 |
2001 | 5 | 6 | 11 |
2002 | 7 | 7 | 14 |
2003 | 7 | 9 | 16 |
2004 | 12 | 16 | 28 |
2005 | 11 | 9 | 20 |
2006 | 10 | 13 | 23 |
2007 | 24 | 15 | 39 |
2008 | 19 | 24 | 43 |
2009 | 27 | 23 | 50 |
2010 | 15 | 29 | 44 |
2011 | 31 | 25 | 56 |
2012 | 18 | 34 | 52 |
2013 | 39 | 34 | 73 |
2014 | 32 | 43 | 75 |
2015 | 21 | 31 | 52 |
2016 | 20 | 36 | 56 |
2017 | 14 | 29 | 43 |
2018 | 17 | 42 | 59 |
2019 | 17 | 30 | 47 |
2020 | 16 | 30 | 46 |
2021 | 20 | 34 | 54 |
2022 | 12 | 30 | 42 |
2023 | 2 | 20 | 22 |
2024 | 0 | 2 | 2 |
Below are the most recent publications written about "Fluorodeoxyglucose F18" by people in Profiles.
-
Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma. Blood Adv. 2024 02 13; 8(3):736-745.
-
Mineralocorticoid Receptor Antagonism by Eplerenone and Arterial Inflammation in HIV: The MIRABELLA HIV Study. JAMA Cardiol. 2024 Feb 01; 9(2):189-194.
-
Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images. J Alzheimers Dis. 2024; 97(1):421-433.
-
Can FDG PET/CT predict AV nodal recovery in cardiac sarcoidosis? J Nucl Cardiol. 2023 Dec; 30(6):2501-2503.
-
FDG-PET/CT and rest myocardial perfusion imaging to predict high-degree atrioventricular block recovery in cardiac sarcoidosis. J Nucl Cardiol. 2023 Dec; 30(6):2490-2500.
-
Development of an online calculator for the prediction of seizure freedom following pediatric hemispherectomy using the Hemispherectomy Outcome Prediction Scale (HOPS). Epilepsia. 2024 Jan; 65(1):46-56.
-
The Canadian Study of Arterial Inflammation in Patients with Diabetes and Recent Vascular Events, Evaluation of Colchicine Effectiveness (CADENCE): protocol for a randomised, double-blind, placebo-controlled trial. BMJ Open. 2023 11 10; 13(11):e074463.
-
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma. Br J Haematol. 2024 02; 204(2):514-524.
-
Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma. Hematol Oncol. 2024 Jan; 42(1):e3231.
-
Rate of benign nodule resection in a lung cancer screening program. Clin Imaging. 2023 Dec; 104:109984.